Investigational drug · Phase 2
ADX-629
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alcohol Hepatitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
9
Any phase or sponsor naming "ADX-629"
First trial start
2024
Nov 4, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ADX-629", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alcohol Hepatitis
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "ADX-629" as an intervention, largest first.
Aldeyra Therapeutics, Inc.Industry
NCT05392192 · 51 participants · Start Apr 7, 2022 · Primary completion Apr 13, 2023
Drug: ADX-629; Placebo · For: Chronic Cough
Sites: San Diego, California; San Jose, California; Hollywood, Florida · 14 sites in all
Aldeyra Therapeutics, Inc.Industry
NCT05487404 · 26 participants · Start Nov 15, 2021 · Primary completion May 29, 2022
Drug: ADX-629; Placebo · For: Ethanol Intoxication
Sites: Cincinnati, Ohio
Aldeyra Therapeutics, Inc.Industry
NCT04847544 · 11 participants · Start Mar 31, 2021 · Primary completion Oct 15, 2021
Drug: ADX-629; Placebo · For: Covid19
Sites: Miami, Florida
Aldeyra Therapeutics, Inc.Industry
NCT04908514 · 10 participants · Start May 7, 2021 · Primary completion Jan 21, 2022
Drug: ADX-629 · For: Plaque Psoriasis
Sites: San Diego, California
University of NebraskaAcademic, hospital or other
NCT05443685 · 8 participants · Start Jan 2, 2023 · Primary completion Apr 1, 2026
Drug: ADX-629 · For: Sjogren-Larsson Syndrome
Sites: Omaha, Nebraska
Aldeyra Therapeutics, Inc.Industry
NCT04728711 · 8 participants · Start Jan 9, 2021 · Primary completion Jan 18, 2022
Drug: ADX-629; Placebo · For: Atopic Asthma
Sites: Mississauga, Canada
Aldeyra Therapeutics, Inc.Industry
NCT05717920 · 8 participants · Start Feb 15, 2023 · Primary completion Nov 21, 2023
Drug: ADX-629 (Open-label) · For: Atopic Dermatitis
Sites: Bexley, Ohio
Aldeyra Therapeutics, Inc.Industry
NCT06685692 · 4 participants · Start Nov 4, 2024 · Primary completion Jun 18, 2025
Drug: ADX-629; ADX-629 · For: Alcohol Hepatitis
Sites: Bradenton, Florida; Tampa, Florida; Dallas, Texas · 6 sites in all
Aldeyra Therapeutics, Inc.Industry
NCT05599815 · 0 participants · Start Jan 2023 · Primary completion May 2023
Drug: ADX-629 · For: Nephrotic Syndrome
Sites: Northridge, California; Aurora, Colorado; Lauderdale Lakes, Florida · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A novel reactive aldehyde species inhibitor prevents the deleterious effects of ethanol in an animal model of alcoholic liver disease.
Duryee MJ, Aripova N, Hunter CD, et al. · Int Immunopharmacol 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.